Urgent

Suxamethonium apnoea

Plasma cholinesterase deficiency · Perioperative & Anaesthesia
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Prolonged neuromuscular paralysis after suxamethonium (or mivacurium) caused by reduced or abnormal plasma (pseudo)cholinesterase activity, which normally metabolises the drug. Apnoea may last from many minutes to several hours depending on genotype.

Red flags

  • Attempted extubation with inadequate spontaneous ventilation
  • Awareness while paralysed if sedation inadequate
  • Homozygous atypical genotype with block lasting hours
  • Co-existing acquired causes compounding the deficiency

Assessment

Differential diagnosis

  • Inherited atypical butyrylcholinesterase (heterozygous or homozygous variants)
  • Acquired low cholinesterase (liver disease, pregnancy, malnutrition, renal failure, malignancy)
  • Drug-induced inhibition (organophosphates, ecothiopate, metoclopramide, oral contraceptives)
  • Residual non-depolarising block or dual (phase II) block from large/repeated suxamethonium doses
  • Other causes of delayed emergence (opioid/sedative, hypothermia, hypercapnia)

Investigations

  • Peripheral nerve stimulator / quantitative train-of-four to confirm ongoing block
  • Clinical signs of inadequate reversal (no spontaneous respiration, flaccidity)
  • Later: plasma cholinesterase activity and dibucaine number
  • Genotyping of butyrylcholinesterase variants
  • ABG to exclude hypercapnia/hypoxia contribution
  • Review drug and family history

Management

  • Recognise failure to resume spontaneous ventilation after suxamethonium
  • Keep the patient intubated/ventilated and fully oxygenated
  • Maintain anaesthesia and sedation so the patient is unaware while paralysed
  • Confirm the diagnosis with a nerve stimulator showing persistent block
  • Do NOT give further depolarising or non-depolarising relaxants
  • Continue mechanical ventilation and supportive care until neuromuscular function returns
  • Monitor train-of-four recovery and extubate only when fully reversed (sustained TOF ratio >0.9, adequate tidal volumes/grip)
  • Send blood for cholinesterase activity and dibucaine number after recovery
  • Document clearly, counsel the patient, and refer family for screening
  • Issue written warning / alert and advise a medical alert record

Drugs & doses

Maintain sedation e.g. propofol infusion 2-4 mg/kg/h or volatile while ventilated
No reversal agent treats the block directly; sugammadex does NOT reverse suxamethonium
Avoid further suxamethonium and mivacurium
Fresh frozen plasma or purified cholinesterase is generally NOT recommended (supportive ventilation preferred)
Analgesia as required while sedated

Disposition

Transfer intubated and sedated to recovery/critical care for continued ventilation until full neuromuscular recovery; document, counsel and refer the patient and family for enzyme testing.

Complications & pitfalls

  • Accidental awareness under paralysis
  • Hypoxaemia/hypercapnia from premature extubation
  • Aspiration if airway unprotected
  • Psychological sequelae
  • Missed diagnosis in untested relatives

Exam pearls

  • The treatment is time and ventilation, not a reversal drug
  • Sedate the paralysed patient to prevent awareness; a nerve stimulator confirms the diagnosis
  • Dibucaine number reflects genotype (quality), not quantity, of enzyme
  • Mivacurium is also metabolised by the same enzyme and will be prolonged
  • Formal diagnosis and family screening via a cholinesterase reference unit is essential

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.